{
    "organizations": [],
    "uuid": "7f005e5a98d86523553ea49f0f4e93d3db4bf361",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-regneurosearch-and-teva-pharmaceut/brief-regneurosearch-and-teva-pharmaceutical-international-enter-into-agreement-on-outstanding-obligations-idUSFWN1SN0XK",
    "ord_in_thread": 0,
    "title": "BRIEF-RegNeurosearch And Teva Pharmaceutical International Enter Into Agreement On Outstanding Obligations",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Neurosearch A/S:\n* REG-NEUROSEARCH AND TEVA PHARMACEUTICAL INTERNATIONAL ENTER INTO AGREEMENT ON OUTSTANDING OBLIGATIONS\n* AGREEMENT TO RELEASE TEVA FROM OUTSTANDING OBLIGATIONS PURSUANT TO 2012 AGREEMENT CONCERNING TRANSFER OF CO’S RIGHTS IN AND TO PRIDOPIDINE\n* PROVIDED AGREEMENT IS COMPLETED,CO’S FINANCIAL EXPECTATIONS FOR 2018 WILL BE AMENDED FROM LOSS OF DKK 3.5-4.5 MILLION TO LOSS OF DKK 0.8-1.8 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-17T01:31:00.000+03:00",
    "crawled": "2018-05-17T14:36:39.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "neurosearch",
        "teva",
        "pharmaceutical",
        "international",
        "enter",
        "agreement",
        "outstanding",
        "obligation",
        "agreement",
        "release",
        "teva",
        "outstanding",
        "obligation",
        "pursuant",
        "agreement",
        "concerning",
        "transfer",
        "co",
        "right",
        "pridopidine",
        "provided",
        "agreement",
        "completed",
        "co",
        "financial",
        "expectation",
        "amended",
        "loss",
        "dkk",
        "million",
        "loss",
        "dkk",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}